WuXi Biologics: Spotlight On Property Disposal And Operating Metrics (Rating Upgrade)
WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...
China's WuXi Biologics to sell Irish vaccine facility to Merck for $500 million
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about $500 million. The Financial Times had reported in October that WuXi and WuXi ...
Merck to buy vaccine plant from WuXi Biologics: report
WuXi Biologics (OTCPK:WXIBF) is reportedly selling its vaccine facility in Ireland to Merck (NYSE:MRK) as part of a previously announced plan to divest some of its assets. The China-based contract ...
WuXi Biologics: Buy Rating Supported by Strong Performance, Strategic Growth, and Increased Target Price
CMB International Securities analyst Jill Wu has maintained their bullish stance on WXIBF stock, giving a Buy rating on January 13.Stay Ahead ...
BioWorld18d
Wuxi Bio licenses trispecific T-cell engager to Candid for $925M
Wuxi Biologics Co. Ltd. is licensing a preclinical trispecific T-cell engager to Candid Therapeutics Inc. in a deal worth up to $925 million plus royalties.